

CLEAR ROLES – NO CHANNEL CONFLICT

- you remain the **local distributor / importer**
- you retain responsibility for **local regulatory compliance**
- concile.global acts as **platform and coordination partner**

Existing national distribution models remain **fully unaffected**.

HOW THE MODEL WORKS

- concile.global provides the platform, portfolio access, and coordination
- manufacturers remain the legal manufacturers
- distributors manage local market access, customers, and regulatory requirements

International markets are served **exclusively through local distribution partners**.

TECHNOLOGY DESIGNED FOR REAL-WORLD HEALTHCARE

- quantitative reader devices engineered and manufactured in Germany
- minimal infrastructure requirements
- suitable for decentralized and emerging healthcare environments
- most assays storable at **2–30 °C**

ONE PLATFORM – FLEXIBLE MARKET OPPORTUNITIES

With concile.global you can:

- start with selected assays
- launch in specific regions or segments
- expand step by step
- build a differentiated local diagnostics offering

Without developing your own reader technology.

Let's talk

www.concile.global

**One global platform.
Built for local markets.**

Interested in becoming a **distribution, import or manufacturing partner?**

Contact us to discuss your market, portfolio focus, and partnership model.

concile

Exclusive distribution partner:
concile global AB
Karlsbodavägen 39
168 67 Bromma Stockholm, Sweden

concile

Quantitative Point-of-Care Diagnostics

**One global platform.
Built for local markets.**

Build your local diagnostics portfolio on a proven platform **The platform combines:**

concile.global is an international diagnostics platform that enables distributors and importers to build and expand local point-of-care portfolios based on quantitative rapid diagnostics.

- robust reader technology developed and manufactured in Germany
- a broad assay portfolio from established international manufacturers
- an innovation driven product philosophy
- a clear distributor-based market model

All on one scalable global platform.

A strong ecosystem behind the platform

concile GmbH, optricon GmbH, and IDL Biotech form the backbone of the concile.global platform.

concile GmbH is a Germany-based diagnostics company with long-standing experience in quantitative point-of-care testing. Over nearly two decades, concile has successfully introduced innovative diagnostic products into routine clinical use and established a broad international partner network.

optricon GmbH, headquartered in Germany, specializes in the development and manufacturing of optical reader systems for quantitative evaluation of rapid tests. As a technology partner, optricon provides reader platforms, technology transfer, calibration management, and long-term technical support throughout the entire device lifecycle.

IDL Biotech, based in Sweden, is an established in-vitro diagnostics manufacturer with a strong focus on oncology and infectious disease diagnostics. Its portfolio includes clinically validated rapid assays such as UBC® Rapid, designed to deliver meaningful diagnostic information quickly and non-invasively.

Together, these partners combine diagnostic expertise, robust technology, regulatory know-how, and long-term market experience within one scalable platform.

Why distributors work with concile.global

QUANTITATIVE RAPID DIAGNOSTICS

Move beyond qualitative rapid tests.

Deliver reliable, quantitative results at the point of care.

BROAD AND EXPANDABLE PORTFOLIO

Access a continuously growing assay portfolio across multiple indication areas, including:

- ✓ infection & inflammation
- ✓ cardiac markers
- ✓ oncology
- ✓ hormones & deficiencies
- ✓ reader devices installed in multiple markets internationally
- ✓ designed for routine clinical use
- ✓ stable, scalable, and reliable

PROVEN PLATFORM



SPLA2-IIA

The sPLA2-IIA assay is a quantitative rapid test for the assessment of cardiovascular risk by measuring secretory phospholipase A2 group IIA, a marker associated with inflammatory processes in atherosclerosis. Elevated sPLA2-IIA levels have been linked to increased cardiovascular risk and can support clinical decision-making at the point of care. The assay is compatible with concile quantitative reader systems, providing fast and objective results in routine practice.

UBC® RAPID

UBC® Rapid is a quantitative point-of-care test for the diagnosis and monitoring of bladder cancer. The assay detects soluble fragments of cytokeratin 8 and 18 in urine, biomarkers that may be elevated even in early stages of disease. With results available within minutes and quantitative readout via concile reader devices, UBC® Rapid enables non-invasive, clinically actionable testing.

HPV HIGH RISK

The HPV High Risk assay is an innovative rapid diagnostic test designed to support early detection of HPV-associated malignancies. It identifies antibodies linked to high-risk HPV types implicated in cervical and other anogenital or oropharyngeal cancers. Quantitative evaluation on concile reader platforms supports objective risk assessment directly at the point of care.